The cannabis sector as a whole is currently in the midst of a boom with the recent positive news of full legalization in Canada, but the medicinal sector of the market is also doing exceptionally well as companies develop new products leveraging CBD. The healthcare market has seen an uptick in consumers searching for alternative medicines, and cannabis has positioned itself very well to take advantage of this new demand. Leaders in the industry are expanding their market reach with new products and effective marketing campaigns in various states where medicinal cannabis is legal. Additionally, the loophole of CBD's ambiguity when it comes to legality has allowed companies to tap into markets where Cannabis is otherwise unavailable. The global medical cannabis market is expected to top $20 billion by 2025, according to data from Coherent Market Insights. Active Companies from around the market with current developments this week include: Pyramidion Technology Group, Inc. (OTC: PYTG), MariMed Inc. (OTC: MRMD), Aphria Inc. (NYSE: APHA) (TSX: APHA), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), India Globalization Capial Inc. (OTC: IGCC).

Pyramidion Technology Group, Inc. (OTCPK:PYTG) BREAKING NEWS: Pyramidion Technology Group today announces that Dr. Canasi, practicing internal medicine physician, advocate of medical marijuana, Cannabidiol (CBD), and other alternative medicines, is the latest addition to the specialist-comprised PYTG, Leafywell (Leafywell.com), Board of Advisors.

Leafywell (Leafywell.com), a subsidiary of PYTG (OTC: "PYTG"), handles the production, manufacturing, and distribution of hemp-based Cannabidiol (CBD) products such as tinctures, creams, lotions, edible candies, at both the wholesale and retail level. In the retail market, products are found at Leafywell.com, and both select retail outlets and medical offices.

The current advisory board composition of PYTG consists of multiple currently-practicing medical professionals including board-certified cardiologist and board-certified internal medicine physician, Dr. Mark Sabbota, family medicine specialist, Dr. Michael McKenzie, MD, Dr. David M. Feldbaum MD, FACS, certified in vascular surgery by the American Board of Surgery, and board-certified Surgical Neurophysiologist, Antonio A. Sama, in addition to other industry-specific board members.

The latest board addition, Dr. Javier J. Canasi, is an internal medicine physician with an active patient-treating medical practice. Dr. Canasi is an advocate of alternative medicine including the both hemp-based CBD products, marijuana-based CBD, and medicinal marijuana, when appropriate for the particular medical condition.

Dr. Canasi, when asked, "How do you view the role of CBD in medical treatment plans?", Dr. Canasi responded candidly, "I appreciate all types of medicine that help patients achieve their treatment goals and we are fortunate to live in a world in which we have options, healthy options. I am a strong advocate of incorporating CBD into a treatment, when appropriate, and in some cases, it is used as a stand-alone treatment and in others I suggest to my patients a mix of CBD along with a regimen of medicinal marijuana or other medicines. CBD can be incorporated to manage a selection of types of pain, including chronic pain."

Dr. Canasi's medical practice offers for purchase a selection of Leafywell (Leafywell.com) products. The wide range of Leafywell products available at Dr. Canasi's office include tinctures ranging from low-concentration compositions to high-concentration compositions, edible gummy candies, lotions, creams, and others.